Name	Epirubicin
Description	Epirubicin (4'-Epidoxorubicin) is an anthracycline antibiotic that acts as a Topoisomerase II inhibitor. It exerts its antitumor effects by intercalating into DNA base pairs, inhibiting DNA replication and transcription, and inducing DNA strand breaks/apoptosis. Epirubicin is widely used in the treatment of breast, gastric, lung, and ovarian cancers.
In vitro	In human hepatoma G2 cells, Epirubicin exhibits cytotoxicity (24 h IC50=1.6 μg/mL), induces apoptosis, and upregulates catalase (+50%), GSH-Px (+110%), and SOD (+135–172%) activities [3]. It inhibits DNA/RNA/protein synthesis by complexing with DNA, primarily killing S-phase cells, while high concentrations affect G1/M/G2 phases and membrane integrity [1].
In vivo	In a human breast carcinoma R-27 xenograft model, systemic administration of Epirubicin at a dose of 3.5 mg/kg resulted in a 74.4% reduction in tumor mass. The compound shows broad clinical activity across various malignancies, including malignant lymphomas, lung cancer, and gastrointestinal tumors [4][5].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 100 mg/mL (183.99 mM), Sonication is recommended.
Keywords	Pharmorubicin PFS. \| IMI-28 \| IMI28 \| Epirubicin \| epidoxorubicin \| epidorubicin \| epiADR \| EPI \| brand name: Ellence \| 4-epidoxorubicin HCl
Related Compound Libraries	Approved Drug Library

Epirubicin NEW

Product Introduction